Adriamycin. A new anticancer drug with significant clinical activity.
about
Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expressionChemotherapy-enhanced inflammation may lead to the failure of therapy and metastasisProtective effect of silymarin against chemical-induced cardiotoxicityCardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycinEchocardiography in adriamycin cardiotoxicitySystolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemiaAnthracycline cardiomyopathy in children: report of two casesElectrocardiographic changes after adriamycin chemotherapyDoxorubicin-induced hypotension in the beagle dogElectrocardiographic changes following adriamycin treatmentDose response evaluation of adriamycin in human neoplasiaA phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokineticsCombination chemotherapy with adriamycin and cis-diamminedichloroplatinum in patients with neoplastic diseasesProbing the dynamics of doxorubicin-DNA intercalation during the initial activation of apoptosis by fluorescence lifetime imaging microscopy (FLIM)Structural effects and translocation of doxorubicin in a DPPC/Chol bilayer: the role of cholesterolClinical Translation of Nanomedicine.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Electron spin resonance investigation of semiquinone radicals formed from the reaction of ubiquinone 0 with human oxyhemoglobin.Liposomal encapsulated anthracyclines: new therapeutic horizons.Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study.Hematologic toxicosis associated with doxorubicin administration in cats.A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.Preclinical toxicity of the new antineoplastic agent, ametantrone acetate, in mice and dogs.Doxorubicin plus cisplatin in the treatment of apudomas.Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.Anthracyclines and the heart.A sandwiched microarray platform for benchtop cell-based high throughput screening.Identifying Mazama gouazoubira (Artiodactyla; Cervidae) chromosomes involved in rearrangements induced by doxorubicinCombination of micellar electrokinetic and high-performance liquid chromatographies to assess age-related changes in the in vitro metabolism of Fischer 344 rat liver.Ozone-Oxidative Preconditioning Prevents Doxorubicin-induced Cardiotoxicity in Sprague-Dawley RatsAnalysis of doxorubicin uptake in single human leukemia K562 cells using capillary electrophoresis coupled with laser-induced fluorescence detection.Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticlesClinical comparison of the nitrosoureas.An A,B,C,D of cancer chemotherapy.Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.Modulation of CD4 T cell function by soluble MHC II-peptide chimeras.Ras puts the brake on doxorubicin-mediated cell death in p53-expressing cellsThe use of scalp hypothermia in the prevention of doxorubicin-induced hair loss.Cardiac damage induced by 2-amino-3-methyl-imidazo[4,5-f]quinoline in nonhuman primates.
P2860
Q24791372-7D22B507-05F0-4A68-828A-C059D2D3BF60Q26858839-6267785F-7E73-4F63-A203-3F270451A5E2Q28079909-25E406A4-1AFB-49D9-965C-15F504D258ECQ28320393-680294C3-FB4D-472C-B502-01985F492D55Q28323660-D3D0FA56-E949-41E7-B150-FDE7713628C1Q28323777-C4C946F2-94F3-4FC1-A2DB-5ADE927A8266Q28323816-F362B2DC-FA77-449D-B391-5F3F77849629Q28325647-E231F3CA-7F14-4C77-8DA8-6FFB8E52EDD5Q28327791-8B725849-B336-434B-B1A6-CCA046049BF8Q28328529-EA48DA36-A830-4A5F-858C-CD88445B4E8AQ28331491-3D2C4A15-9F76-4AA9-AEDC-3420442036A5Q28331720-C39051AB-06D2-4D91-B4BB-072D6BF4E738Q28334842-0BFB7B17-39A5-4C0C-B09C-15F88089AD98Q28483863-700B011F-B026-4163-AC67-7628C04ACFCCQ28742602-5A19F3C8-F29D-4D80-A6A5-9A62DEB394EBQ30355939-04361DC3-6A81-48C0-8486-79DD747DB772Q30366990-323A6D84-57C7-499A-8C46-9B97A225E0B0Q30780542-F94E22F5-3359-48AD-A701-C53C71929C69Q31935290-38F58801-A537-4BCF-915D-7A2D5E74CB2DQ33341789-7F4B04C1-8CDE-472C-9BB1-2847241D6080Q33356128-3356A37D-91C8-4907-90E3-03319A7C5DF7Q33382443-A0FFF2AE-C0CA-4C16-8586-60C10AF9132BQ33459076-15DC8F56-3C73-44C9-9757-388B6BF1588FQ33460123-22520D19-BA6A-4467-89A2-7F779EE6A37AQ33475888-8B207BB7-1BCC-422C-94AB-27995F3EC0FFQ33476090-4864B740-6BCE-4743-96C1-1D1A87DBF092Q33613628-0C84DB9D-E44A-4E01-A8C2-4DA508444376Q33724982-D4B51DE9-6199-4C6A-9086-939A9664AF33Q33846726-0CAFC0E4-CFB1-49E5-A7B4-653314442DEBQ33957499-69F294CF-472D-4191-9733-F2D293F54D31Q33982934-A3BAE2F6-FC11-4FFA-AED3-FAA2915BC7FEQ34000218-D151BC79-D4CB-442C-8919-55431141AFBDQ34028831-AA236E63-353E-4007-8392-587DE243BBC6Q34043318-45034FDF-957E-4CFD-8C08-3EBDE211CAD7Q34052652-73E12F0A-23C6-4246-8A6B-0A04913ED40CQ34062253-1B9260A7-D52A-4DE7-82F9-8301C2DE231DQ34560511-EC3372FF-BC0F-41B3-A1EF-C47D72FC69EFQ34606299-F9C41BC5-412A-41DA-A38F-037E9CAB70B4Q34708880-29B8154D-4187-44CE-AC82-FF541DB05116Q35031855-E51B13BA-F900-4DB6-BB52-30ECDFF4C8D0
P2860
Adriamycin. A new anticancer drug with significant clinical activity.
description
1974 nî lūn-bûn
@nan
1974 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1974 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1974年の論文
@ja
1974年論文
@yue
1974年論文
@zh-hant
1974年論文
@zh-hk
1974年論文
@zh-mo
1974年論文
@zh-tw
1974年论文
@wuu
name
Adriamycin. A new anticancer drug with significant clinical activity.
@ast
Adriamycin. A new anticancer drug with significant clinical activity.
@en
Adriamycin. A new anticancer drug with significant clinical activity.
@nl
type
label
Adriamycin. A new anticancer drug with significant clinical activity.
@ast
Adriamycin. A new anticancer drug with significant clinical activity.
@en
Adriamycin. A new anticancer drug with significant clinical activity.
@nl
prefLabel
Adriamycin. A new anticancer drug with significant clinical activity.
@ast
Adriamycin. A new anticancer drug with significant clinical activity.
@en
Adriamycin. A new anticancer drug with significant clinical activity.
@nl
P1476
Adriamycin. A new anticancer drug with significant clinical activity.
@en
P2093
P304
P356
10.7326/0003-4819-80-2-249
P407
P577
1974-02-01T00:00:00Z